C4 Therapeutics Reaffirms Cemsidomide Timelines but Near-Term Catalysts Remain Limited

What happened

C4 Therapeutics reported Q3 2026 results and confirmed its cemsidomide programs are on schedule: Phase 2 MOMENTUM enrollment completion expected Q1 2027 with initial ORR data in 2H27, and the Phase 1b elranatamab combination has completed its first safety cohort with all-cohort data due mid-2027. Additionally, a new Phase 1b combination trial with standard-of-care myeloma therapies is planned to initiate in 1H27. These updates merely reaffirm prior guidance and do not provide new efficacy or safety data. The stock's investment case remains heavily dependent on the upcoming all-cohort combo data and eventual MOMENTUM readout, with no near-term catalyst beyond the previously promised 2H26 dose-escalation update, which the release does not mention specifically. While the announcement reduces operational uncertainty, it does not change the fundamental valuation challenge that cemsidomide still needs to demonstrate durability and differentiated tolerability against larger cereblon modulator competitors.

Implication

Investors should treat this release as a check-the-box update rather than a catalyst. The lack of new data means the stock's near-term movement will hinge on the promised 2H26 dose-escalation progress update for the elranatamab combination, which management has still not detailed. If that update is clean and MOMENTUM remains on track, the base case of a $4.30 implied value could hold, but the bear case of $3.00 remains plausible if timelines slip or data disappoint. The addition of the SOC combo trial provides optionality but also increases cash burn, and the company still admits it will need substantial capital before approval. At the current price around $4.08, the risk/reward is not compelling for new positions; consider accumulating only on a pullback toward the $3.20 attractive entry level identified in the DeepValue report.

Thesis delta

No material shift to the investment thesis. The news confirms prior guidance on MOMENTUM enrollment and the elranatamab combo all-cohort data, but offers no new evidence to improve confidence in cemsidomide's differentiation or durability. The planned SOC combination trial is a minor positive addition but does not alter the timeline-driven risk profile or valuation.